DPX-Survivac + cyclophosphamide + epacadostat

DPX-Survivac + cyclophosphamide + epacadostat is a **three-drug combination immunotherapy regimen** currently being investigated primarily for the treatment of advanced, recurrent ovarian cancer. The regimen combines: - DPX-Survivac, a peptide-based therapeutic cancer vaccine that uses the DepoVax (DPX) lipid-based platform to deliver survivin-derived antigens, stimulating the immune system to produce survivin-specific cytotoxic T cells against tumors overexpressing survivin[1][2][3][4][5][6][7]. - Cyclophosphamide, administered in low-dose metronomic fashion as an immunomodulatory agent, which enhances the vaccine-induced immune response by reducing immunosuppressive cells such as regulatory T cells and favoring effector T cell expansion[1][2][7]. - Epacadostat, a small molecule inhibitor targeting the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), intended to reduce tumor-mediated immunosuppression and further promote T-cell activity. The combination is designed to generate **polyfunctional, tumor-specific T cells** for robust tumor infiltration and cytolytic activity, enhanced by the immunomodulatory and immune checkpoint inhibition effects of cyclophosphamide and epacadostat, respectively[1][2][3][4][5][6][7]. Clinical trials are mainly in ovarian cancer, with supportive activity noted for stable disease and tumor shrinkage and an acceptable safety profile in early-phase studies[1].

Brand names

none

Other names

Maveropepimut-S + cyclophosphamide + epacadostat